Tumor necrosis factor receptor 2 M196R polymorphism in rheumatoid arthritis and osteoarthritis: Relationship with sTNFR2 levels and clinical features

Rheumatology International

Volumn 27, Issue 1, 2006, Pages 53-59

  Oregón Romero, Edith ^a   Vázquez Del Mercado, Mónica ^a   Navarro Hernández, Rosa Elena ^a   Torres Carrillo, Norma ^a   Martínez Bonilla, Gloria ^b   Estrada García, Iris ^c   Rangel Villalobos, Héctor ^a   Muñoz Valle, José Francisco ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Osteoarthritis; Polymorphism; Rheumatoid arthritis; Tumor necrosis factor receptor 2

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; GENE FREQUENCY; GENOTYPE; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RHEUMATOID ARTHRITIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CHOLESTEROL; DISABILITY EVALUATION; GENOTYPE; HUMANS; MEXICO; MIDDLE AGED; OSTEOARTHRITIS, KNEE; POLYMORPHISM, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 33750450860     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0159-7     Document Type: Article

References (29)

1. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358:903-911
2. Goldring SR (2003) Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology 42(Suppl 2):ii11-ii16
3. Goldring MB (2000) The role of the chondrocyte in osteoarthritis. Arthritis Rheum 43:1916-1926
4. Sandell LJ, Aigner T (2001) Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res 3:107-113
5. MacEwan DJ (2002) TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14:477-492
6. Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ, Middleton PG (2003) Tumor necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation 76:1742-1749
7. Till A, Rosenstiel P, Krippner-Heidenreich A, Mascheretti-Croucher S, Croucher PJP, Schäfer H, Scheurich P, Seegert D, Schreiber S (2005) The Met-196→Arg variation of human tumor necrosis receptor 2 (TNFR2) affects TNF-α-induced apoptosis by impaired NF-κB signaling and target gene expression. J Biol Chem 280:5994-6004
8. Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y, Otsuka T, Sawabe T, Harashima S, Nagasawa K, Niho Y (2001) Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: molecular and funtional analysis. Arthritis Rheum 44:2819-2827
9. Al-Ansari AS, Ollier WER, Villareal J, Ordi J, Tech LS, Hajeer AH (2000) Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens 55:97-99
10. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 35:1160-1169
11. Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T, Yazici H, Guerne PA (1997) Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic disease and correlate with disease activity. J Rheumatol 24:303-308
12. Rutkowski P, Kamińska J, Kowalska M, Ruka W, Steffen J (2003) Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 84:151-159
13. Hajilooi M, Sanati A, Ahmadieh A, Ghofraniha A, Massoud A (2004) Circulating ICAM-1, VCAM-1, E-selectin, P-selectine, and TNFR2 in patients with coronary artery disease. Immunol Invest 33:263-275
14. Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon-Segovia D (1993) How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol 11:117-121
15. Abello-Banfi M, Cardiel MH, Ruiz-Mercado R, Alarcon-Segovia D (1994) Quality of life in rheumatoid arthritis: validation of a Spanish version of the Arthritis Impact Measurement Scales (Spanish-AIMS). J Rheumatol 21:1250-1255
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
17. Bellamy N, Buchanan WW, Goldsmith CH (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833-1840
18. Lequesne MG, Mery C, Samson M, Gerard P (1987) Indexes of severity for osteoarthritis of the hip and knee. Validation - value in comparison with other assessment test. Scand J Rheumatol (Suppl 65):85-89
19. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
20. Komata T, Tsuchiva N, Matsushita M, Hagiwara K, Tokunaga K (1999) Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. Tissue Antigens 53:527-533
21. Barton A, John S, Ollier WER, Silman A, Worthington J (2001) Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. Arthritis Rheum 44:61-65
22. Bridges SL, Jenq G, Moran M, Kuffner T, Whitworth WC, McNicholl J (2002) Single-nucleotide polymorphisms in tumor necrosis factor receptor genes. Definition of novel haplotypes and racial/ethnic differences. Arthritis Rheum 46:2045-2050
23. van der Helm-van Mil AHM, Dieudé P, Schonkeren JJM, Cornélis F, Huizinga TWJ (2004) No association between tumour necrosis factor receptor type 2 gene polymorphism and rheumatoid arthritis severity: a comparison of the extreme of phenotypes. Rheumatology 43:1232-1234
24. Goldring MB, Birkhead J, Sandell LJ (1990) Synergistic regulation of collagen gene expression in human chondrocytes by tumor necrosis factor-α and interleukin-1β. Ann NY Acad Sci 580:536-539
25. Dursunoǧlu D, Evrengül H, Bülent P, Tanriverdi H, Çobancara V, Kaftan A, Kihç M (2005) Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 25:241-245
26. Wallberg-Jonsson S, Cederfelt M, Rantapää-Dahlqvist S (2000) Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: a 8 year follow up study. J Rheumatol 27:71-75
27. Vázquez-Del Mercado M, Muñoz-Valle JF, Santos A, Bernard-Medina AG, Martínez-Bonilla G, Pazca JA, Ruiz-García H, Orozco-Alcalá J, Orozco-Barocio G, Quezada-Arellano D, Gurrola-Díaz C, Nuño-González P, Best-Aguilera CR, Chávez-Castellanos R, Panduro A (2002) Evaluation of lipid profile, macular toxicity and clinical manifestations according to APO E genotype in systemic lupus erythematosus and rheumatoid arthritis patients treated with chloroquine. Scand J Rheumatol 31:32-37
28. Waldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026-2033
29. Barrera P, Boerbooms AM, Janssen EM, Sauerwein RE, Gallati H, Mulder J, de Boo T, Demacker PN, van de Putte LB, van der Meer JW (1993) Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 36:1070-1079